NeuroMetrix, Inc. (the “Company”) (Nasdaq:NURO), a medical device
company focused on the treatment and management of the neurological
complications of diabetes, today announced the launch of www.DPNCheck.com.
The website is an important online resource that will help support the
growing domestic and international DPNCheck® business.
DPNCheck is a fast, accurate and quantitative point-of-care test for
diabetic peripheral neuropathy, or DPN. The DPNCheck test addresses an
unmet medical need for better and more cost-effective screening,
diagnosing and monitoring of DPN. This complication affects over 50% of
people with diabetes and leads to foot ulcers and limb amputation, as
well as severe pain and an overall reduction in patient quality of life.
www.DPNCheck.com
contains content to help healthcare providers, managed care
organizations, and other stakeholders understand DPN and the clinical
benefits of early detection and management with DPNCheck. The resources
available on the site include monographs, references to scientific
studies, and video instruction for DPNCheck testing and interpretation
of results.
“We are pleased with the growing acceptance of DPNCheck among Medicare
Advantage plans where the test is used in the clinically and financially
important risk adjustment process,” said Shai N. Gozani M.D., Ph.D.,
President and Chief Executive Officer of NeuroMetrix. “We believe that a
branded DPNCheck website will help our efforts to grow this business. We
are also gearing up for a launch of DPNCheck into the Japanese market
where we are partnering with Omron Healthcare. The website will support
Omron’s efforts as well as those of our other international partners. We
believe that DPNCheck represents an attractive high-margin business
opportunity that complements SENSUS and our other therapeutic
initiatives.”
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment and management of
chronic pain, peripheral neuropathies, and associated neurological
disorders. The Company is presently focused on diabetic neuropathies,
which affect over 50% of people with diabetes. If left untreated,
diabetic neuropathies trigger foot ulcers that may require amputation
and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for treating chronic
pain, focusing on physicians managing patients with painful diabetic
neuropathy. The company also markets the DPNCheck® device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. For more information, please
visit http://www.neurometrix.com.
Copyright Business Wire 2014